Aptevo Therapeutics announced that it has entered into securities purchase agreements with certain healthcare-focused and institutional investors to purchase (i) 9,090,910 shares of its common stock or pre-funded warrants in lieu thereof and (ii) warrants to purchase up to an aggregate of 18,181,820 shares of its common stock at a purchase price of $0.33 per share and associated Common Warrant in a registered direct offering priced at-the-market under Nasdaq rules. Each share of common stock is being offered together with two Common Warrants, each to purchase one share of common stock. The Common Warrants will have an exercise price of $0.33 per share, are exercisable upon stockholder approval, and will expire five years following the date stockholder approval.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APVO:
- Aptevo, Alligator Bioscience announce data from Phase 1 ALG.APV-527 trial
- Aptevo Therapeutics files to sell 13.51M shares of common stock
- Aptevo Therapeutics initiates Phase 1b/2 ‘RAINIER’ AML trial
- Aptevo Therapeutics reports Q2 EPS ($1.67) vs. ($53.95) last year
- Aptevo (APVO) Q2 Earnings Cheat Sheet